StemCell Therapy

Most of the cells in your body are highly specialized. A kidney cell, for example, can multiply and create new kidney tissue, but it cant turn into a bone cell or neuron. Stem cells, on the other hand, are able to differentiate into many different cell types.

The primary function of adult stem cells, which reside throughout the body, is to maintain and repair tissues. Their innate brilliance lies in their ability to zero in on areas of damage or degeneration. Signaled by inflammation, they migrate wherever theyre needed and, taking cues from surrounding cells, facilitate healing, restoration, and regeneration.

Stem cell therapy used to involve embryonic cells, which understandably generated a lot of controversy. Todays research focuses on non-embryonic adult mesenchymal stem cellsand there is nothing controversial about using your own cells in a safe and therapeutic manner. Adult stems cells may be derived from bone marrow. However, this isnt a particularly abundant source, and cells must be cultured over several days tocreate enough for therapeutic use. Furthermore, their number and viability decline dramatically with age. More recently, fat was discovered to be a far richer, much more accessible repository of robust adult stem cells.

New technologies now make it possible to remove a few ounces of a patients fat through a mini liposuction procedure, separate out the stem cells in a special process that yields extremely high numbers of viable cells, and return them back into that persons body via an IV or injection.

Performed in a physicians office, under sedation and local anesthesia and using a sterile closed system technology so the cells never come into contact with the environment, there is minimal discomfort and risk of infection. And because the stem cells come from the patients own body, there is no risk of rejection or disease transmission.

Whitaker Wellness is proud to announce that we have partnered with the Newport Beach Stem Cell Treatment Center, allowing us to offer non-embryonic adult mesenchymal stemcell therapy to our patients.

Read this article:
Adult Stem Cell Therapy, Stem Cell Therapies Future Medicine

All treatments performed at Lung Institute utlize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

The treatments, claims and other information contained on this page and LungInstitute.com have not been evaluated or approved by the FDA. Any individual that accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

View post:
Lung Institute | Stem Cell Therapy For Lung Disease

Menu Appointment Contact Us Visit Us Patient Portal

the pain ends here

Call (210) 293-3136

Start Your Treatment

Adult Stem Cell Overview

Platelet Rich Plasma

Stem Cells in the News

Read more

Read more

Regenerative Medicine

Frequently Asked Questions

The body of man [is] Gods drug-store and [has] in it all liquids, drugs, lubricating oils, opiates, acids, and anti-acids, and every sort of drug that the wisdom of God thought necessary for human happiness and health.

A. T. Still, Founder of Osteopathic Medicine

See what everyone is saying about STEM CELL Therapy in the news!!!

Stem Cells in the news

Comparing Joint Pain Solutions Thanks to modern medicine, we are living longer than ever! Everyone wants to live a long, happy life but longevity does have some downsides. Arthritis impacts nearly

Read more

Regenerative medicine is an increasingly important, incredibly promising area of medicine which focuses on improving the repair and regeneration of damaged tissue. Organ and bone marrow transplants were early forms

Read more

DECEMBER 2015 SAN ANTONIO SCENE The Stem Cell Orthopedic Institute of Texas offers stem cell and platelet rich plasma (PRP) procedures as viable alternatives for individuals suffering from joint pain, joint

Read more

THE STEM CELL ORTHOPEDIC INSTITUTEOF TEXASat the medical center in San Antonio offersSTEM CELLandPLATELET RICH PLASMA (PRP) Therapies to help individuals suffering from joint pain, joint and tendon degeneration, and

Read more

You may be a candidate for STEM CELL Therapy. Call (210) 293-3136 today to schedule your medicalevaluation. Courteous Patient Advocatesare standing by to answer your questions.

Start Your Treatment

The STEM CELL ORTHOPEDIC INSTITUTE of Texas 5282 Medical Drive Suite 200 San Antonio, TX 78229

Phone: Call (210) 293-3136

See the article here:
Stem Cell Therapy, Surgery, Transplant & Treatment | Stem Cell

A1 Stem Cells makes available the potency of Embryonic Stem Cells to treat major degenerative diseases. We offer tumor treatment and cancer treatments. We also address treatment for diabetes, treatment for depression, treatment for stroke and many more. (see our stem cells treatment page) Further more we encourage a proactive approach to heath care. Our team developed an anti aging therapy program to help your body rejuvenate.

A1 Stem Cells, beyond addressing the symptoms of your condition, cares to address its causes. We take it as our mission to find the source of your ailments, whether there are metal, pollutants or parasites of all sorts, then free you from these accumulated toxins, and finally restore the functionality of your organs thanks to our embryonic stem cells treatment. We will also counsel you so that you can maintain your regained well being and vitality once back home.

It is now understood that most diseases are the result of an accumulation of toxins and parasites that ineluctably damage our organs through time. It is also the major cause of aging and all its related ailments. The proposed embryonic stem cell treatment reverses the damages caused to the body. Upon injection, the cells trigger the body to repair itself, one organ at a time, bringing youth and wellness back from the inside out. The stem cell therapy have also been found more efficient if the toxins that caused the ailment at first have been thoroughly removed, thus preventing a possible future set-back. This is especially clear for all our cancer treatment.

The A1 Stem Cells offer is a complete and unique treatment that includes:

Each of the diseases listed here have been thoroughly studied by our medical partners and biochemists. You can browse our testimony page to see the extent of what can be achieved when an ill body is relieved from the toxins accumulated through time and then recharged with the regenerative power of the stem cells.

If you don't find your ailment described in our site, please inquire with our repre-sentative who will get back to you shortly with the advise of our experts.

When I first consulted with A1 Stem Cells doctor, they diagnosed a tumor that they quickly removed with their cleanse protocol and stem cell treatment. I dont remember when was the time I felt like I feel now. I have gained at least 20 years worth of energy.

Go here to see the original:
Stem Cell Therapy, Anti-Aging and Prevention

Can Stem Cell Studies help treat Chronic Obstructive Pulmonary Disease (COPD)?

Today, new COPD stem cell treatments and advances in research are giving new hope to people affected by this disease. The COPD treatments for Stem Cell Clinical Studies are being studied for their efficacy in improving the complications in patients with Chronic Obstructive Pulmonary Disease, through the use of stem cells. These stem cell COPD treatments may help patients who dont respond to typical drug treatment.

To learn more about becoming a patient and receiving stem cell therapy through StemGenex Medical Group, please contact one of our patient advocates at (800) 609-7795 or fill out the contact form on this page.

Chronic obstructive lung disease (COPD) describes a group of lung conditions (diseases) that make it difficult to empty the air out of the lungs. This difficulty can lead to shortness of breath (also called breathlessness) or the feeling of being tired. COPD is a word that can be used to describe a person with chronic bronchitis, emphysema or a combination of these. COPD is a different condition from asthma, but it can be difficult to distinguish between COPD and chronic asthma.

The most common cause of Chronic Obstructive Pulmonary Disease is cigarette smoking, but there are many other causes. Inhaling smoke or air pollutants can cause the mucus glands that line the bronchial tubes (bronchi) to produce more mucus than normal, and can cause the walls of the bronchi to thicken and swell (inflame). This increase in mucus causes you to cough, frequently resulting in raising mucus (or phlegm). COPD can develop if small amounts of these irritants are inhaled over a long period of time or if large amounts are inhaled over a short period of time.

Environmental factors and genetics may also cause COPD. For example, heavy exposure to certain dusts at work, chemicals and indoor or outdoor air pollution can contribute to COPD. The reason why some smokers never develop COPD and why some non-smokers get COPD is not fully understood. Family genes or heredity probably play a major role in who develops COPD.

There are 4 stages of COPD. They are :

The diagnosis of COPD depends upon the presence of one or more of the symptoms of the disease.

The following are facts cited from the American Lung Association(www.lungusa.org) and U.S. Centers for Disease Control and Prevention(www.cdc.gov)

Stem cells are unprogrammed cells in the human body that can be described as "shape shifters." These cells have the ability to change or differentiate into other types of cells. Stem cells are at the center of a new field of science called regenerative medicine. Because stem cells can become bone, muscle, cartilage and other specialized types of cells, they have the potential to treat many diseases, including Parkinson's, Alzheimer's, COPD, Diabetes and more.

StemGenex offers stem cell therapy using Adult stem cells only.There are four known types of stem cells:

Stem cell therapy is an intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. Many medical researchers believe that stem cell treatments have the potential to change the face of human disease and alleviate suffering. The ability of stem cells to self-renew and give rise to subsequent generations with variable degrees of differentiation capacities, offers significant potential for generation of tissues that can potentially replace diseases and damaged areas in the body, with minimal risk of rejection and side effects.

StemGenex is currently studying adipose stem cell therapy as a new alternative treatment to help manage the complications of COPD. The stem cells harvested from a patient have the potential to replace countless cells of the body, lung tissue included. These stem cells may heal the body by replacing ones plagued with disease, regenerating new cells, and suppressing the immune systems macrophage response which engulf and digest the dying cells of the lungs. Current research in adult stem cell therapy has shown that restoration of damaged cells through this treatment is possible. This breakthrough in regenerative medicine shines a light of hope on those battling this degenerative disease. Improvements have been seen in the following symptoms after treatment:

StemGenex is studying potential ways to directly target the conditions and complications themselves. These studies consist of multiple ways to deliver the highest amount of activated stem cells to the areas patients need them most. When stem cells are studied through StemGenex, as potential therapy for COPD, there are multiple ways they can be administered:

Yes. Scientists around the world believe there is enough evidence to suggest that stem cells hold real potential as a therapy for COPD. This evidence comes from research in animals and from a handful of early clinical trials. They believe that it is now time for a concerted effort in stem cell research and an international effort to support clinical trials of stem cells for COPD.

No. There are currently no FDA approved stem cell therapies for COPD disease. All stem cell therapies for COPD disease are currently unproven, experimental therapies. This means that the FDA does not know whether stem cells are effective for people with COPD disease. The only way to determine the effectiveness of stem cell therapy is through the type of clinical studies and trials which are currently being conducted in the US.

One of the goals of StemGenex, through our stem cell studies, is to understand what a particular stem cell therapy might be able to achieve. For example, does it have the potential for slowing the disease's progression, replacing damaged cells and memories, or both? With this goal in mind, StemGenex continues to study these diseases and the full effect of stem cell therapy on each disease. Anecdotally, these results have been overwhelmingly positive but there is more that needs to be done to determine the exact effectiveness of these therapies.

After stem cells have been administered into someones body they have to make their way to the correct place (e.g. area of damage) and then have their desired effect. This process takes time and although it is difficult to predict exactly how long, it is likely that it will take several weeks or months on average to see the full desired effect.

Yes, a stem cell therapy may be repeated. Current studies indicate the strong possibility of a cumulative effect from multiple stem cell therapies a patient received for their condition. Long-term studies will attempt to better understand this in detail.

Original post:
Stem Cell Therapy Studies for COPD - StemGenex

What Are Stem Cells?

Stem cells are your bodys repair team. They divide limitlessly and go around your body providing nourishment to all your other cells. As long as youre alive, stem cell ensure all the cells in your body are healthy, happy, and serving you well. There are two types of stem cells embryonic stem cells and adult stem cells.

As the name suggest, these stem cells come from the embryos that develop from eggs that have been fertilized in vitro. In vitro fertilization clinics donate these stem cells for research purposes with the informed consent of the donors. Its important to note that these eggs are not derived from eggs fertilized in a womans body. These particular cells are isolated from the inner mast of a blastocyst. These pluripotent stem cells can give rise to any type of cell in the fully developed body. In the lab, embryonic stem cells keep reproducing themselves until they are turned into specific types of cells. In the body, these cells eventually disappear, so a human adult body no longer contains cells that can generate any kind of cell. A problem often encountered with embryonic stem cells is tissue rejection, which is similar to the rejection in a liver or blood transplant. This can limit the therapeutic usefulness of these particular stem cells.

Adult stem cells are found in small numbers within most adult tissues like bone marrow or fat. They are the maintenance crew of your body they make sure everything is in tip-top shape by being multipotent in that they give rise to several kinds of cells in their home tissues. They regenerate cells damaged by disease, injury, and everyday wear and tear. By dividing, they become specialized to repair or replace surrounding differentiated cells. Just like embryonic stem cells, adult stem cells have the ability to differentiate into more than one cell type, but unlike embryonic stem cells, they are often restricted to certain lineages. There are three types of adult stem cells. Two types are located within the bone marrow, and the other type is known as a fat stem cell.

Stem cells are removed from the bone marrow at the back of the patients pelvis via suction. The substance is then removed using a syringe. The process is only slightly uncomfortable with local anesthetic. Typically, only 2 oz. of bone marrow aspirate is required. This aspirate contains platelets, mesenchymal stem cells, and other kinds of stem cells that are used in adult stem cell therapy. After its taken, it is placed inside a special container, which is then placed into a machine known as a centrifuge. This begins spinning at a high speed until the platelets and stem cells separate from the other blood products. This particular concentration of bone marrow is called BMAC or Bone Marrow Aspiration Concentrate. This is then re-introduced into the injured area during stem cell therapy.

Once the BMAC is reintroduced into the injured area, the platelets are released and start to go to work repairing the area. They signal proteins and growth factors that activate the stem cells. These signal proteins and growth factors are called cytokines, which are sort of the traffic directors of the operation, telling the stem cells where to go to repair your body.

The typical repair process is two to three months. However, in most cases, great improvement can be seen before then. About four to six weeks after the stem cell injection, the patient will receive a platelet-rich plasma injection on the afflicted area followed by another injection four to six weeks after that. Patients are advised to minimize alcohol consumption as it can deter healing. To boost healing, patients are advised to take a compound called StemXcell, which contains supplements such as carnosine, blueberry extract, vitamin D3, and green tea extract.

Excerpt from:
Stem Cell Therapy - Stem MD I Advanced Orthopedics

THURSDAY, June 9, 2016 (HealthDay News) -- A treatment combining chemotherapy and a stem cell transplant could represent a major advance against aggressive multiple sclerosis, experts say.

This new treatment destroys the immune system with chemo and rebuilds it with the patient's own stem cells. Researchers say it stopped MS relapses and progression in 23 of 24 patients.

According to the results of this small trial, these 23 patients no longer needed medication to control their MS. Moreover, eight showed continued improvement for nearly eight years.

"These patients had highly active MS with lots of relapses and lots of ongoing damage to their brain, but we've been able to stop that," said lead researcher Dr. Harold Atkins. He is an associate professor of clinical hematology at the University of Ottawa in Canada.

The results are noteworthy, Atkins said. "There are lots of drugs and treatments available that are able to slow the disease or temperately halt it, but this one seems to be significant in that it had a long-lasting effect," he explained.

However, it's not for everybody with MS. "Because of the side effects and the rigor of treatment, it is something that should be used with those with the most aggressive MS before they have real damage. This won't work for patients who have advanced disabilities or are in a wheelchair," he added.

And, because the immune system is destroyed, patients have no defense against infections.

Still, Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, N.Y., thinks this therapy is a "breakthrough" in MS treatment.

"For these patients, the turnaround was extremely dramatic," Wright said. But the treatment must be tried in more patients before it can be widely used.

"A larger sample size is necessary," Wright added. "Because the treatment is toxic and potentially life-threatening, you need to make sure before you tout this as a panacea for advanced MS that it benefits a large population of patients."

MS is a chronic inflammatory disease of the central nervous system. It can lead to vision problems, muscle weakness, trouble with coordination and balance, and thinking and memory problems, according to the U.S. National Institutes of Health.

The new treatment involves collecting a patient's bone marrow stem cells, purifying them and freezing them. The patient is then subjected to high levels of chemotherapy. This is similar to the treatment used to treat some lymphomas, Atkins said.

The chemotherapy is so strong that it crosses the blood-brain barrier and eliminates damaged immune cells from the central nervous system, he explained.

Once that's done, the stem cells are thawed and returned to the patient to start the process of rebuilding the immune system, Atkins said.

A larger trial is planned, but this treatment can be used right now in hospitals that do stem cell transplants for lymphoma, according to Atkins.

In this trial, the researchers treated 24 MS patients, aged 18 to 50. Their disease was progressing rapidly and they weren't helped by the usual MS medications.

While improvement was notable, side effects were significant. One patient died from a liver infection, and eight had moderate toxic effects. Fourteen had mild side effects, the study authors said.

After the stem cell transplant, patients remain hospitalized as the immune system begins to recover -- usually about four weeks, Atkins said. It then takes up to nine months at home to fully recover and resume normal activities.

Pointing to the therapy's success, Atkins said patients had at least one relapse a year before treatment but none during follow-up of between four and 13 years.

Also, the patients had a total of 93 brain lesions before treatment. After treatment, only one new lesion was detected, according to the study.

Moreover, three years after the therapy, six patients were able to reduce or discontinue their disability insurance and return to work or school, Atkins said.

The report was published online June 9 in the journal The Lancet.

SOURCES: Harold Atkins, M.D., associate professor, clinical hematology, University of Ottawa, Canada; Paul Wright, M.D., chairman, neurology, North Shore University Hospital, Manhasset, N.Y.; June 9, 2016, The Lancet, online

News stories are provided by HealthDay and do not reflect the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, the U.S. Department of Health and Human Services, or federal policy.

The rest is here:
MS Stem Cell Therapy Succeeds But Poses Risks

What is stem cell therapy?

Stem cell therapy is the use of your bodys own stem cells to repair a joint. The procedure involves four main steps.

After the procedure it is recommended that you have a follow up appointment with Norwood Day Surgery 3 days, 2 weeks, 2 months and 6 months after your procedure. Your doctor will discuss your progress with you and may utilise standardised pain tests such as WOMAC or HOOS depending on the joint where you received treatment.

In a study at our practice 100osteoarthritis patients were treated with stem cell therapy and assessed each month for 6 months. It was reported that over 75% of patients treated, showed a significant improvement between 50 100% in pain and mobility of the joint.

Approximately 15% of patients treated were non-responders and had an improvement of less than 20% after 3 months.

The repair process takes time with the improvement at its maximum level by 6 months. Whether young or old the improvement after receiving stem cell therapy was the same. It is too early to determine the lifespan of the treatment as this treatment has only been available since 2009, with only 10% of our patients needing a second treatment.

Many thousands of patients with osteoarthritis have now been treated with stem cell therapy. We know that it is a safe procedure if done carefully.

Minor adverse events have been observed on the day of the procedure in a small percentage of patients and include: slight fever, rash, euphoria followed by a transient depression and cramps in the toes and feet.

Common liposuction short-term side effects may include: abdominal pain, bruising (which may last up to two weeks), and leakage of anaesthetic fluid for 24 hours. One case of bleeding has occurred from a sensitivity to intravenous injection of stromal vascular fraction.

The rest is here:
Stem Cell Therapy or Knee Replacement Adelaide

Adult stem cells stored at a laboratory. A new treatment led to long-standing remission for MS patients. Photograph: MedicImage/Alamy

A radical and risky stem cell therapy has been shown to halt and even reverse some of the symptoms of those worst affected by multiple sclerosis, a disease that in many people has proved untreatable.

Doctors in Canada conducted an experimental stem cell transplant with 24 patients who were expected to be confined to a wheelchair within 10 years. After receiving the treatment most of the patients regained control of their lives, becoming able to walk, play sport and drive.

To succeed, the transplant required the destruction and rebooting of each persons immune system such a high risk approach that one of the patients died. But the others, followed up for between four and 13 years, had no further progression of the disease. The disease normally entails worsening symptoms over time.

To the surprise of their doctors, some patients recovered functions that had been eroded by the disease, including their sight and balance. Six returned to work or college, five married or became engaged and two had children using banked sperm or eggs, as the aggressive treatment had made them infertile.

Mark Freedman, a neurologist at the University of Ottawa, who co-led the trial, said he would not say his patients were cured. I hesitate to use the c-word. A cure would be stopping all disease moving forward and repairing all damage that has occurred. As far as we can ascertain no new damage seems to occur beyond the treatment and patients dont need to take any medication, so in that sense I think it has induced a long-standing remission. Some patients did recover substantial function and it allowed them to do things they couldnt do for years, but others did not.

However, the long-term results of the trial in Canada, published in the Lancet medical journal, have been universally applauded by scientists and support groups and will lead to a worldwide clamour for the transplants to be more widely available.

Stephen Minger, a stem cell biologist and independent consultant, said: The clinical results are truly impressive, in some cases close to being curative, though we need longer-term follow-up to know for certain whether the patients continue to do well or if there is a chance of relapse. And of course this trial will need replication by other groups too.

For a life-long progressive disease like MS with few treatment options this is really exciting data. It offers the hope of having a long-lasting treatment which may halt disease progression though, again, this is a very invasive therapy and not without risks. Still I would consider it a breakthrough therapy, and the clinical group and the patients should be congratulated for this success.

The doctors say this treatment is not for everyone with MS because of the dangers. Modern drugs can control the symptoms for most people with the disease, but they do not work in people who have a sudden onset of very aggressive disease with frequent relapses. Freedman said the transplants they had been doing in Ontario were suitable for perhaps 5-10% of MS patients. It is needless if the disease can be controlled with mild medicines that dont carry those kind of risks, he said.

Multiple sclerosis is caused by a malfunction of the immune system, which ordinarily defends the body against bacteria, viruses and disease. The disease attacks instead the insulating myelin sheath, which is essential for the proper functioning of the nervous system. Those who are badly affected, usually young, progressively lose the ability to control their limbs.

Stem cell transplants have been carried out before in MS patients, but those people had a relapse after a couple of years. Never before have doctors used the aggressive drug regimen used in Canada a therapy that totally destroys the immune system, putting patients at risk for a while from life-threatening infections.

The patient in the transplant group who died suffered very severe liver damage and a bacterial infection which caused sepsis, or blood poisoning.

In the process, the Canadian doctors removed stem cells from the bone marrow of the patients and processed these in a laboratory. They then used a combination of three toxic drugs to destroy each patients immune system before transplanting the cleaned-up stem cells in to the body.

There were some fairly profound and wonderful changes that some of them experienced, said Freedman. Some people hadnt walked and started walking. Some people who had lost their vision were seeing. More than half the patients returned to gainful employment, maintained their relationships, got back their drivers licence.

Some, however, had disease that was progressing like a runaway train, he said. They continued to get worse for a couple of years but then their disease also stopped progressing. But nobody developed any new inflammation at all, he said. Their brain scans showed no new lesions, he added.

People with MS have been going to clinics in Mexico and elsewhere in the world in search of stem cell treatments they hope will turn out to bring a cure. But doctors emphasised that the regimen used in Canada, being very dangerous, had to be restricted to very specialised centres, and needed to be tested in more people before it became more widely available.

In the UK, Paolo Muraro, a neurologist at Imperial College London, who met Freedman last week to discuss the results, is hoping to start his own international trial, involving about 180 people with MS. That trial would try a slightly less intense drug regime in the hope of reducing the risks, he said. He was still seeking funding for it and said the treatment might have been more widely available by now if it had been a drug.

Related: 'It was really the last option': one woman's multiple sclerosis recovery

The treatment does not rely on any proprietary drug, so it is not a treatment that has received any support from the pharmaceutical industry. People like Mark Freedman and myself have had to work with very limited resources to try to develop this treatment really from charitable funding and academia-driven units.

The Canadian results were indeed very good news, he said, although, he added, it was important to avoid raising false hopes, because of the risks and the need for more trials.

The study in Ontario was funded by the MS Society of Canada. Charities in the UK also welcomed the findings but warned that people with MS who might think of having a stem cell transplant should speak to their doctor.

Emma Gray, head of clinical trials at the MS Society, said: This treatment does offer hope, but its also an aggressive procedure that comes with substantial risks and requires specialist aftercare. If anyone is considering [a stem cell transplant] wed recommend they speak to their neurologist.

Amy Bowen, at the Multiple Sclerosis Trust, said the results were extremely interesting and encouraging. She added: Stem cell therapy is still very experimental, and is not suitable for everyone. However, it could be a potentially very effective therapy, holding great promise for people living with MS. Its also a long way from being a routine treatment for MS.

Read the original here:
Stem cell therapy gives hope to MS patients | Society ...

MS brain lesion as seen on an MRI.

By obliterating the broken immune systems of patients with severe forms of multiple sclerosis, then sowing fresh, defect-free systems with transplanted stem cells, researchers can thwart the degenerative autoimmune diseasebut it comes at a price.

In a small phase II trial of 24 MS patients, the treatment halted or reversed the disease in 70 percent of patients for three years after the transplant. Eight patients saw that improvement last for seven and a half years, researchers report in the Lancet. This means that some of those patients went from being wheelchair-bound to walking and being active again. But to reach that success, many suffered through severe side effects, such as life threatening infections and organ damage from toxicity brought on by the aggressive chemotherapy required to annihilate the bodys immune system. One patient died from complications of the treatment, which represents a four percent fatality rate.

Moreover, while the risks may be worthwhile to some patients with rapidly progressing forms of MSa small percentage of MS patientsthe researchers also caution that the trial was small and did not include a control group.

Larger clinical trials will be important to confirm these results, study coauthor Mark Freedman of University of Ottawa said in a statement. Since this is an aggressive treatment, the potential benefits should be weighed against the risks of serious complications associated with [this stem cell transplant], and this treatment should only be offered in specialist centres experienced both in multiple sclerosis treatment and stem cell therapy, or as part of a clinical trial, he added.

Similar treatments have been used before in other trials, which also showed positivethough not as dramaticresults. Generally, researchers start by harvesting a patients haematopoietic stem cells, which give rise to the bodys immune system. Then researchers use chemotherapy to knock back the patients misbehaving immune system. In MS patients, defective immune responses rip off the insulation from nerve cells in the brain and spinal cord, causing inflammation, lesions, and nerve damage that eventually lead to physical and mental disabilities. The disease can progress in bouts over decades or continuously over months.

With that defective immune system weakened, researchers can replace the patient's stem cells, which are distant enough predecessors that they don't carry the glitches that trigger MS. Thus, they can potentially spawn a flaw-free immune system.

Freedman and colleagues took this general treatment strategy a step further by not just knocking back the patients defective immune system, but byannihilating it completely with a cocktail of powerful drugs.

It's important to stress that this is a very early study, Stephen Minger, a stem cell biologist not involved with the study, told the BBC. Nevertheless, the clinical results are truly impressive, in some cases close to being curative.

Freedman added that future research will be geared not only to replicating the results in larger trials, but to figuring out how to make it safer for patients.

Lancet, 2016. DOI: 10.1016/S0140-6736(16)30169-6 (About DOIs).

Follow this link:
Risky stem cell treatment reverses MS in 70% of patients ...

Featured in the News Across the Nation: Dr. Dennis Lox, an Expert in Sports & Regenerative Medicine, Discusses Knee Stem Cell Therapy, Hip Stem Cell Therapyand Ankle Stem Cell Therapy.

Since 1990, Dennis M. Lox, M.D. has been helping patients increase their quality of life by reducing their pain. He emphasizes non-surgical treatments and appropriate use of medications, if needed.

Many patients are turning to stem cell therapy as a means of nonsurgical joint pain relief when their mobility and quality of life are severely affected by conditions like osteoarthritis, torn tendons, and injured ligaments. Dennis M. Lox, M.D. specializes in this progressive, innovative treatment that may be able to help you return to an active, fulfilling life.

Each week, Dr. Dennis Lox receives inquiries from aroundthe worldregarding stem cell therapy.

TRAVEL ARRANGEMENTS CAN BE MADE FOR YOU LOCAL OR INTERNATIONAL

Visit our Press Room

Stem cell therapy for joint injuries and osteoarthritis is suited for many individuals, fromprofessional athletes to active seniors. Adult mesenchymal stem cells, not embryonic stem cells, are used in this procedure, which is performed right in the comfort of Dr. Loxs state-of-the-art clinic. The cells are simply extracted from the patients own body (typically from bone marrow or adipose/ fat tissue), processed in our office, and injected directly into the site of injury. Conditions that can be addressed with stem cell treatment include osteoarthritis, degenerative disc disease, knee joint issues (such as meniscus tears), shoulder damage (such as rotator cuff injuries), hip problems (such as labral tears), and tendonitis, among others. For many patients, a stem cell procedure in the knee, hip, shoulder, or another area of the body relieves pain, increases mobility, and may be able to delay or eliminate the need for more aggressive treatments like joint replacement surgery.

If you have questions about adult stem cell therapy for joint injuries and arthritis, how the procedure is performed, and how the stem cells work to repair injured joints and tissues, Dr. Lox would be happy to educate you about the entire process.

If you are searching for effective, nonsurgical joint replacement alternatives, regenerative therapies like stem cell treatments and PRP therapy may be the ideal solution. At Florida Spine and Sports Medicine, we focus on helping patients return to mobile, independent lives without the need for the risks and downtime associated with highly invasive surgery.PRP Therapy, Stem Cell Treatments & Other Joint Replacement Alternatives for Patients in Tampa, Clearwater, New Port Richey & throughout the U.S.A. and the world.

PRP (platelet rich plasma) therapy can be used alone, or adult stem cell therapy is often used in conjunction with PRP as a means of promoting healing in degenerated or injured joints, cartilage, muscles, and tendons. From knee pain to spine pain, there are a wide range of conditions that may respond to these forms of regenerative medicine. Some of the most common issues that Dr. Lox treats at Florida Spine and Sports Medicine include knee arthritis, meniscal tears, S/I joint pain, hip conditions, shoulder pain, and ankle pain, among others.

If you live in Clearwater, St. Petersburg, New Port Richey, Tampa, or anywhere else in the nation and would like to schedule a consultation to discuss PRP therapy, stem cell therapy, or other alternatives to joint surgery with Dr. Lox, please contact Florida Spine and Sports Medicine today.

More:
Tampa Stem Cell Therapy | PRP | Knee | Joint Replacement ...

Stem cells are unquestionably some of the most amazing cells in the human body. These are undifferentiated cells that do not have a direct blueprint or specific destiny. The can become differentiated into specialized cells anywhere throughout the body. They are classified as 2 different types of cells, those that are from embryonic origin and those called adult stem cells.

In the developing embryo, these cells differentiate into ectoderm, endoderm, and mesoderm. These give rise to our spine, nerves, and all our organs. Adult stem cells are primarily used to repair, replenish, and regenerate tissues.

Historically, stem cells can come from a variety of tissues. These include umbilical cord, fetal tissue, bone marrow, or the best source as adipose or fat cells.

Adipose derived stem cells have the highest numbers of cells when collected and tested compared to all others . This is by far the preferred method of stem cell therapy because of sheer numbers and the fact that they are coming from your own body. This is called autologous therapy.

Stem cell research in this country has been in existence for over 60 years. There are a wide range of studies and articles describing its dramatic benefit for chronic diseases. Many of these publications are available for you to read on my website.

In performing stem cell therapy, extremely strict guidelines mus be followed in coordination with a specialized clinical trial review board. This ensures accuracy, sterility, and quality control of the procedure. This information gathered from the procedure, including various forms of documentation can be used for medical publication at a later date. Physician notes and procedure as well as a questionnaire filled out by patients periodically are part of this process. This enables the highest level of procedure and documentation possible.

The procedure takes approximately one and a half hours to complete. Initially, patients are examined, appropriate blood or other testing is done and reviewed and schedule is made to begin procedure.

Typically, stem cell therapy is done within 2 weeks of initial consultation.

On the day of procedure, stem cells are extracted from abdominal belly fat, love handles, or around the buttocks, this takes 5-10 minutes then patients sit and relax while the processing is done. It is then washed and centrifuged 3 times to allow separation of cells and harvest stem cells. At the end of the procedure, microscopic analysis can estimate the number of stem cells available of injection. Injection can be done either into joint, connective tissue, muscle or for all other organs or systemic diseases, intravenously. Intranasal technique is also used for MS, Parkinsons and Alzheimers disease.

Diseases that are currently available for treatment with stem cells include:

Arthritis Alzheimers disease

COPD Critical Limb Ischemia

Diabetes Erectile Dysfunction

Frailty Syndrome Liver Failure

Localized Ischemia Lupus

Multiple Sclerosis Parkinsons Disease

Pulmonary Fibrosis Renal Failure

Rheumatoid Arthritis Stroke

Vascular Insufficiency Heart Failure

Follow this link:
Stem Cell Therapy / drcalapai.net

Source: http://www.abc57.com By: Vahid Sadrzadeh

Video Link Here: ABC57 News See the Difference Michiana

An unprecedented stem cell procedure was performed today at a veterinary clinic in Michiana. [Click link above to watch video].

The surgery was for5-year-old German Shepherd, Nike, and set anexample of how stem cell therapy is changing modern medicine.

Although it took merely 30 minutes, it was toughfor Jayne Stommel to watch,Nikes owner and trainer.

Stommel traveled from Indianapolis to South Bend hoping the operation would relieve her 5-year-old super dog of arthritic pain and ensure Nike could continue working for many more years.

Stommelslove for training rescue dogs began long before Guinness and Nike came along.

After seeing the devastation of 9/11 firsthand, Stommel says shediscovered her calling.

With a little bit of research and the right dog,that dream became a reality.

Nike, is one of only 150 certified FEMA trained rescue dogs in the nation that actively works to find survivors of fires, building collapses and natural disasters.

While training at only a year old, Nike was in an accident which ultimately led to arthritis in her hips.

Nike is mid-career, she just turned five. If she doesnt have to stop because the pain in her hips, she should be able to go another four or five years, saidStommel.

Stommel knew in order to prolong Nikes career as long as possible, the stem cell procedure, which was affordable and minimally invasive, was necessary.

It takes a lot of work and training and thats after you find the right dog. They are very unique dogs. Being able to keep her working longer, is very important, saidStommel.

Noticing that Nike was favoring her hip during recent training, Stommelwas recommended to and then sought the help of Dr. Chris Persing and the team at Western Veterinary Clinic on the edge of South Bend.

The treatment was divided into two operations, the first was this morning.

We opened up her abdomen; we found a good healthy layer of fat that we pulled out. I handed that over to a staff so that she could prepare that tissue. To extrude the stem cells, to incubate them, to excite them, to get them ready for a job to do. Later on in the day, we went ahead and used those stem cells to inject in to Nikes hips, says Persing, Associate Veterinarian.

The injection went well and hopes are high for a full recovery.

After a two or three week period, she should be pretty much back to her normal activity and doing the things that she needs to for training again, saidPersing.

And in just two monthsStommels other German Shepherd, Guinness, will be joining that exclusive list of certified FEMA trained rescue K9s.

Until then the two train together, waiting for Nike to join the pack again.

Follow this link:
Stem Cell Worx News

Stem Cell Therapy Plus is also called Live Cell Therapy or Regenerative Medicine.

Anecdotal evidence shows that through the usage of Stem Cell Therapy Plus, improvements can be seen in the following cases of degenerative diseases:

Learn More

Stem cells are cells with the ability to divide for indefinite periods in culture and to give rise to specialized cells. Stem cells have the remarkable potential to develop into many different cell types. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a nerve cell, or a brain cell.

Stem Cell Supplements are developed based on the merits of stem cells and they are applied for degenerative diseases treatments and to stimulate the formation of all the different tissues of the body: muscle, cartilage, tendon, ligament, bone, blood, nerve, organs, etc.

Stem Cell Supplements bring essential anti-ageing, health & beauty benefits by providing necessary elements to the body to improve cellular regeneration, organ rejuvenation and tissue healing.

Learn More

See the rest here:
Stem Cell Therapy in Switzerland Life Cell Injections ...

On this blog I have been writing about stem cells, hyperbaric oxygen (HBOT), and some incredible new observations related to reversing brain inflammation. All of the diseases I listed above and a whole bunch more are tied to persistent inflammation. Inflammation itself is very important to the body. In a healthy person it doesnt persist. It comes in response injury or infection cleans that up then stem cells communicate the need to stop the inflammation and heal. To that extent, these chronic persistent inflammatory conditions are the result of a failure of stem cells to do their job to counter inflammation. I will explain what is keeping them out of the process below and in future posts.

As this following picture demonstrates, the balance of inflammation regulation in the brain is complicated, intricate and precarious. But science has reached a point where we understand a large portion of the regulatory pathways.

[Frontiers in Bioscience 14, 5291-5338, June 1, 2009]

Caption: Microglia are the primary recipients of peripheral inflammatory signals as they reach the brain. Activated microglia initiate an inflammatory cascade by releasing cytokines, chemokines, prostaglandins and reactive nitrogen and oxygen species (RNS and ROS, respectively). Bi-directional exchanges between microglia and astroglia amplify inflammatory signals within the central nervous system (CNS). Cytokines including interleukin (IL)-1, IL-6, tumor necrosis (TNF)-alpha and interferon (IFN)-gamma induce indoleamine 2,3 dioxygenase (IDO), the enzyme responsible for degrading tryptophan, the primary precursor of serotonin (5-HT), into kynurenine, which is eventually metabolized into quinolinic acid (QUIN), a potent NMDA agonist and stimulator of glutamate (Glu) release. Multiple astrocytic functions are compromised due to the excessive exposure to cytokines, prostaglandins, QUIN and RNS/ROS, ultimately leading to downregulation of glutamate transporters, impaired glutamate reuptake, excessive glutamate release and compromised synthesis and release of neurotrophic factors. Oligodendroglia suffer damage due to toxic overexposure to cytokines such as TNF-alpha, and diminished neurotrophic support, both of which promote apoptosis and demyelination. Copious amounts of glutamate are released from astrocytes in the vicinity of extrasynaptic NMDA receptors, whose activation leads to inhibition of BDNF synthesis. Excessive NMDA activation, caused by QUIN and D-serine, is compounded by diminished glutamate reuptake by astrocytes and oligodendroglia. NMDA-mediated excitotoxicity, combined with a consequent decline in neurotrophic support, and an increase in oxidative stress, synergistically disrupts neural plasticity and induces apoptosis (cell death).

So it doesnt matter if we are talking about autism, post-stroke inflammation, Alzheimers, HIV dementia; the central mechanism is largely the same.

Now this is important to understand: if we have persistent inflammation in the brain, what is driving that signal? The immune system has lots of regulatory steps designed to keep it in balance, but despite all the intrinsic safeguards in the system it has lost control. Why?

Some perspective: About 5 years ago I was sitting on a bus with Professor Thayne Sweeten. We were on our way to dinner to relax after a full day of brainstorming as a group of researchers interested in autism. Thayne is a bright guy. His PhD dissertation was Immune Activation and Autoimmunity in Autism. He explained from everything he had seen regarding the immune system of autism; the CSF observations, the increase in neopterin, etc,, that at least a significant subgroup of children had the immunological footprint of a persistent viral pathogen.

I agreed and I still do agree especially after 5 years of discoveries. And it doesnt have to be a virus: many other pathogenic bacteria and fungi could cause the same response. But for simplicity lets just say virus.

We dont have to agree about which virus is persistent in autism, it actually doesnt matter that much. I am surprised to hear myself say that, but after what I have learned in the last few months, I dont think the actual virus is that important. That is because most do not have a specific anti-viral drug (apart from HIV and some Herpes viruses). Even in those cases the drugs are inadequate and something else is needed.

THE IMMUNE SYSTEM IS BLINDED

The picture depicts the blind miraculously being given sight. I would love to see a miracle of immune unblinding in autism, or any of these other disorders. Absent that we need to give it sight medically.

If you read my blog about this last night I spoke about the problem. We have a raging immune response just like we would expect with a viral infection, except it doesnt go away. Why? The immune cells (particularly macrophages) seem to be blind and cannot find the enemy they are looking for. So while they stumble around, unable to find the viral enemies, the entire system stays turned on. And it will stay turned on until either stem cells say enough its time to heal, or until the virus is eliminated.

The evidence is we dont generate enough stem cell response to regulate this type of immune response presumably because the viruses are still present. Therefore, extra stem cells may help cool the immune fires. BUT, and it is an important but, do we want to down-regulate the immune system if a virus is still present? My belief is no.

What we want is to make the virus go away and with that have the immune response naturally calm down.

To do that we have to give sight to the blind and help the macrophages find their targets.

To do this we are working with some of the finest biotech labs in Europe and we believe we have the solution. More on that to come.

A brief but helpful discussion about TNF alpha is on wikipedia. http://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha

Continue reading here:
Stem Cell Therapy | Dr Jeff Bradstreet, MD, MD(H), FAAFP

Regenexx Knee Stem Cell Therapy for Injuries and ArthritisChris Centeno2015-08-07T15:30:40+00:00

The Regenexx family ofnon-surgical stem cell and blood platelet procedures offer next-generation injection treatments for those who are suffering from knee pain or may be facing knee surgery or knee replacement due to common tendon, ligament and bone injuries, arthritis and other degenerative conditions.

As an alternative to knee surgery or knee replacement, Regenexx procedures may help alleviate knee pain and the conditions that cause it with a same-day office injection procedure. Unlike traditional surgery, Regenexx patients are typically encouraged to walk the same day, and most patients experience very little down time from the procedure.

Knee Patient Results | Regenexx SD Procedure Overview | ACL Injuries | Meniscus Tears

This is not a complete list of conditions treated, but the most common knee conditions we have treated throughout the years. If you are experiencing knee pain, injury, or arthritis, please contact us or complete the candidacy form below to learn more about whether the Regenexx Procedures are right for you.

This Regenexx-SD (same-day) bone marrow derived stem cell treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry.

This Regenexx-SD (same-day) bone marrow derived stem cell treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry following treatment for Meniscus Tears.

This data utilizes LEFS (Lower Extremity Functional Scale) data from our knee arthritis patients treated with stem cell injections. Functional questionnaires ask the patients questions such as how well they can walk, run, climb stairs, etc. The improvements following the Regenexx-SD procedure are highly statistically significant.

If you are considering a knee replacement, watch the video in the sidebar of this page and read about how stem cells stack up against knee replacements.

BioMed Research International;Volume 2014, Article ID 370621,.Centeno CJ.

Introduction. We investigated the use of autologous bone marrow concentrate (BMC) with and without an adipose graft, fortreatment of knee osteoarthritis (OA). Methods. Treatment registry data for patients who underwent BMC procedures with andwithout an adipose graft were analyzed. Pre- and posttreatment outcomes of interest included the lower extremity functional scale(LEFS), the numerical pain scale (NPS), and a subjective percentage improvement rating. Multivariate analyses were performedto examine the effects of treatment type adjusting for potential confounding factors. The frequency and type of adverse events(AE) were also examined. Results. 840 procedures were performed, 616 without and 224 with adipose graft. The mean LEFS scoreincreased by 7.9 and 9.8 in the two groups (out of 80), respectively, and the mean NPS score decreased from 4 to 2.6 and from 4.3to 3 in the two groups, respectively. AE rates were 6% and 8.9% in the two groups, respectively. Although pre- and posttreatmentimprovements were statistically significant, the differences between the groups were not. Conclusion. BMC injections for knee OAshowed encouraging outcomes and a low rate of AEs. Addition of an adipose graft to the BMC did not provide a detectible benefitover BMC alone.

Two time Super Bowl Champ Jarvis Greens story. From a young boy struggling to get through a football practice, to a 2X Super Bowl Champion, Jarvis tells his story of pain and struggle following knee surgeries, and his return to form following a Regenexx Stem Cell Procedure.

If you are interested in learning whether you are a good candidate for the Regenexx Procedure, please complete the Regenexx Procedure Candidate Form below or call us at 888-525-3005.

Continue reading here:
Knee Stem Cell Therapy - Surgery & Replacement Alternative

With the onset of Alzheimers disease, information transfer at the synapses (the connection between the nerve cells and extensions) starts to break down, and the number of synapses decreases significantly.

Autoimmune diseases are conditions in which the patients immune system generates cellular and antibody responses to substances and tissues normally present in the body.

In each condition there is chronic obstruction of the flow of air through the airways and out of the lungs, and the obstruction generally is permanent and may be progressive over time.

Rheumatoid Arthritis is an autoimmune disease that attacks the bodys own tissues, specifically the synovium, a thin membrane lining the joints. As a result, joint fluid builds up, causing pain in the joints and inflammation thats systemic.

Parkinson's disease is a chronic progressive neurological disease that affects nerve cells (neurons) in an area of the brain known as the substantia nigra.

Osteoarthritis, or degenerative joint disease, is the most common type of arthritis. It is caused by the degradation of a joints cartilage.

Multiple sclerosis (or MS) is a degenerative disease involving the deterioration of nerve cells. MS attacks the central nervous system (CNS), which is made up of the brain, spinal cord, and optic nerves.

Diabetes is the condition in which the body does not properly process food for use as energy. When you have diabetes, your body either doesn't make enough insulin or can't use its own insulin as well as it should.

Read more here:
Stem Cell Therapy, Stem Cell Treatments, Stem Cell Clinics ...

Mr. Deven Patel President, CEO and Co-founder

Mr. Deven Patel is the President, CEO and Cofounder of GIOSTAR. He has also served as the CEO, President and Board of Directors in highly comprehensive environment of Healthcare Management, Architectural, General Construction, Alternative Energy and multifaceted Internet industries. Apart from serving as CEO and President, Mr. Patel has also served in a key positions of several public and private organizations such as Asian & Pacific American Coalition, Asian Outreach Committee Children Memorial Hospital San Diego, Federation of India Associations, National Federation of Indian American Association, CRY America, Global Organization of People of Indian Origin, Kelly Dean Citizens Awareness Circle, Phillip Redmond Foundation, Lockport Planning Commission.

During his early career, Mr. Patel was involved with the design and construction of several healthcare projects as an architect and a builder. He has also served as a partner for an assisted living and wellness center fostering care for senior citizens suffering from special conditions.

Dr. Anand Srivastava, M.S., Ph.D. Chairman, Cofounder and Chief Scientific Officer

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals.

Dr. Anand Srivastava's success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastava's wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastava's research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and he has been cited extensively by other scientists. Dr. Anand Srivastava's expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the "Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in "WHO IS WHO IN AMERICA" data bank two times, first in 2005 and second in 2010.

Dr. Anand Srivastava's Long Profile

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals.

Dr. Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Companys primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

Giostar is worlds leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a world-renowned authority in the field of Stem cell biology, Cancer, Gene therapy. Several governments including USA, India, China, Turkey, Kuwait, Thailand and many others seek his advice and guidance on drafting their strategic & national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership a group of esteemed scientists and clinicians have developed and established Stem cell therapy for various types of Autoimmune diseases and blood disorders which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe. Giostar is already the official collaborator of Government of Gujarat, India by setting up a state of art stem cell treatment hospital in Surat civil hospital for the less fortunate tribal populace of the southern belt of Gujarat suffering from Sickle Cell Anemia. Several state Governments in India is looking for a collaborative efforts of GIOSTAR and Dr. Anand to develop stem cell transplant program in their respective states.

SUMMARY OF DR. SRIVASTAVAS WORK:

Dr. Anand Srivastavas success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastavas wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastavas research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and he has been cited extensively by other scientists. Dr. Anand Srivastavas expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in WHO IS WHO IN AMERICA data bank two times, first in 2005 and second in 2010.

POSITIONS HELD BY DR. SRIVASTAVA (1997 to Date):

1. Chairman & Cofounder (2008-till date): Global Institute of Stem Cell Therapy and Research, San Diego, CA. USA. 2. Associate Professor: Department of Cellular and Molecular Biology, School of Medicine, University of California Los Angeles (UCLA), CA, USA. 3. Visiting Senior Scientist: Department of Stem Cell Biology, Burnham Research Institute for Medical Science, San Diego, CA, USA. 4. Senior Scientist: Stem Cell Core Facility, The Salk Research Institute, La Jolla, CA, USA. 5. Associate Professor: Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA. 6. Assistant Professor: Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA 7. Honorary Visiting Professor: National Research Institute, Nansei, Mie, JAPAN.

SPECIAL STEM ISSUES OF JOURNALS DEVOTED TO DR. SRIVASTAVA

1. Current Topics of Medicinal Chemistry among top five medicinal chemistry journal devoted its special issue of stem cell to Dr. Srivastava in 2010. 2. Stem Cell International devoted its special issue on stem cells to Dr. Srivastava in 2012.

EXPERT SCIENTIFIC REVIEWER FOR LEADING JOURNALS OF MEDICINE:

Dr. Srivastava is the member of the several scientific review committees and reviewing the research grants. He has written several review articles and scientific manuscripts. He is also the reviewer and editor of several scientific journals.

1. Advances in Stem Cells 2. Current pharmaceutical Design 3. Current Topics in Medicinal Chemistry 4. Stem Cells 5. Stem Cell International 6. Current in Cell Medicine 7. Journal of Stem Cell Research and Therapy 8. Conference Papers in Molecular Biology 9. Journal of Pharmaceutics 10. Current Pharmaceutical Biotechnology 11. Open Journal of Organ Transplant Surgery 12. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 13. Stem Cells and Cloning: Advances and Applications 14. Blood and Lymphatic Cancer: Targets and Therapy 15. Degenerative Neurological and Neuromuscular Disease 16. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 17. Immuno Targets and Therapy 18. Current Vascular Pharmacology 19. Gastrointestinal Cancer: Targets and Therapy 20. Journal of Bioengineering and Biomedical Sciences 21. The Application of Clinical Genetics 22. Journal of Tissue Science & Engineering 23. Neuropsychiatric Disease and Treatment 24. Current Tissue Engineering 25. Hepatic Medicine: Evidence and Research 26. Current Drug Discovery Technologies 27. Current Bioactive Compounds 28. Transplant Research and Risk Management 29. Biosimilars 30. Current Drug Delivery 31. Journal of Experimental Pharmacology 32. Open Journal of Regenerative Medicine 33. Current Diabetes Reviews 34. Journal of Fertilization: In Vitro 35. Clinical and Translational Medicine

FELLOWSHIPS/ AWARDS:

2003 Awarded with NIMA (National Integrated Medical Association) Outstanding Scientist award from NIMA, India. 2003 Awarded with Excellent Scientist Award from Bharat Vikas Parisad, India for continuous excellent performance in the life science research. The 18th International Congress of Clinical Chemistry and Laboratory Medicine Kyoto Excellent Poster Award, Kyoto, Japan. 2002 Best Scientist Award for excellent contribution in the field of life science research from Kayastha Maha Sabha, Varanasi, India. 1998-2000: Long-term STA/JISTEC Award (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship award for two year from government of Japan. 1997-1998: Short-term STA/JISTEC Award (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship Award for three months from government of Japan (October 1997- January 1998). 1997-1998: Awarded with Research Associate-ship award from CSIR (Council of Scientific and Industrial Research) Government of India. 1990-1995: CAS (Center of Advanced Study) Award in Zoology. A doctoral research fellowship award from Government of India.

THE FOLLOWING SUMMARIZES DR. SRIVASTAVAS MAJOR SCIENTIFIC ACHIEVEMENTS:

1. Dr. Srivastava developed the animal material free and serum free Human embryonic Stem cell culture condition to use the Human ES cells to treat the human diseases. 2. Dr. Srivastava for the first time showed that if the ES cell injected into developing fetuses in utero takes participation in development of all body of a living organism. 3. For the first time he showed that ES cell is better accepted by the transplanted animals in comparison to adult stem cells. 4. For the first time he showed the way to generate the high number of pre-erythrocytes using glucocorticoid hormone. Which may be use to treat several blood diseases. 5. For the first time Using ES cells he generated the high number of CD34+ expressing a kind of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune reconstitution and blood diseases. 6. For the first time he showed the molecular mechanism behind the regulation of ES cell differentiation into hematopoietic cells. 7. For the first time he showed that ES cells automatically recognize the damage portion of the brain and can be used to repair the damage brain. 8. For the first time he showed that ES cell can be used to treat the Crohns disease a kind of colon cancer. 9. For the first time, he demonstrated that the mammalian fetuses can be programmed inside the mother uterus to face the challenges of the future possible infection. This finding is very important to develop the advanced therapy for any fatal disease such as cancer and AIDS. Utilizing these techniques, fetuses can be given information about all possible infections and the capability to counter those infections and disease. 10. He has demonstrated for the first time that it is easy to correct the genetic diseases in developing fetus in utero in comparison to adult animals. 11. He has shown for the first time that the lung cancer cells can be treated with the help of plant product curcumin and can be used as effective cancer therapeutic agent. He also demonstrated that how curcumin regulated the genes related to programmed death of cancerous cell. Finding help in development of non-toxic, less expensive, easily available drug for cancer. 12. The biggest problem in the treatment of cancer and other diseases is the non-specific distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava for the first time developed a technique that can help in targeting the diseased tissues using the tissue receptor binding peptide ligands. These techniques can be used for targeted delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the mother uterus without harming the normal tissues of mother and fetus. 13. For the first time, He demonstrated the insertion of foreign pancreas enzyme specific gene promoter into the developing animals embryo and successfully shown the incorporation and regulation of pancreatic enzyme in the control of inserted gene. This is very important finding and proves that the defective genes can be replaced easily and effectively by the normal functional genes during the development of animals. This finding will help in the change of defective genes of insulin hormone, which is present in the pancreas of diabetic patients and many other genetic diseases also. 14. For the first time, He reported the gene sequence of all important pancreatic enzymes (three isoform of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three forms of carboxypeptidases and lipase) and its evolutionary relationship with human. Also,he reported first time the regulation of digestion by these enzymes in the alimentary canal during digestion of proteins in the developing animals. 15. For the first time, He cloned and sequenced two types of human homologue of Vitamin D receptor gene from Japanese flounder, which is most important receptor, which help in the development of bone. Before my report, characters of this gene were not known in Japanese flounder. This finding helped in the understanding of the genetic evolution of mammals. 16. For the first time, he cloned and sequenced the homologue of human placental protein, PP11, and mouse T cell specific, Tcl-30, in pancreas of Japanese flounder, this study suggest that these genes evolved from the fish pancreas and in fish it helps in synthesizing the digestive enzymes but during the evolution its function got changed and work differently in the mammalian placenta. This was very important finding related to this rare gene. 17. For the first time, He has shown that the Hox and sonic hedgehog genes regulate the development of bones and respiratory organs. He also demonstrated that how these genes could be regulated artificially. This was very important finding because it gives the idea that how genes regulate the development of organs. 18. For the first time, He has purified and characterized the human homolog of AAT and ASPT enzymes, which is the basic clinical marker in all the infection and major marker of liver function test. 19. For the first time, he demonstrated the co-ordination of AAT and ASPT enzymes in the production of energy through the amino acids after aerobic respiration. 20. For the first time, he has shown that according to metabolic demand of the body AAT and ASPT genes synthesized additional forms of its isoform to cope up with the extra energy demand and work as an on and off switch.

DR. SRIVASTAVAS EXCELLENCE IN SEVERAL ADVANCED BIOLOGICAL TECHNIQUES:

Techniques related to Human Embryonic Stem Cell Human Embryonic Stem cell culture, Serum free and feeder free hES cell culture, in vitro differentiation of hES cells into neural cells, in vitro differentiation of hES into hematopoietic cells and red blood cells under the control of cytokines. Gene regulation studies using RT-PCR, Real time PCR, Northern blot, Southern blot and in situ hybridization, immunohistochemistry during the differentiation, Cell cycle regulation studies during differentiation of hES cells into hematopoietic and neural cells. Use of siRNA for blocking a specific cell cycle. FACS analysis of differentiated cells and cell shorting. ES cell transfection.

In vivo studies with ES cells Created a mouse model for study the effect of ES cells on damaged brain. Injection of ES cells into mouse brain, tail vein injection, in vivo tracking of ES cell migration. Used the ES cells for repair of damaged brain. Gene and protein regulation during neural cell differentiation. Studies on transcription factors. Histochemical analysis of transplanted ES cells using fluorescent, confocal microscopy and deconvolution microscopy. Created a mouse model for Crohns disease. In vivo migration of ES cells into diseased portion of intestine. Studies on inflammatory cytokines during the repair of Crohns disease with ES cell. Gene regulation studies during this process. Elisa assays for the cytokines. Stem cell niche interaction.

Created in utero mouse model for ES cells transplantation. Used this model to make chimeric animals. Distribution and differentiation of ES cells into developing mouse embryo. FACS and magnetic shorting of ES cells derived CD31+, CD34+, CD45+ cells from the transplanted animal tissues. Gene and protein regulation of in vivo differentiating cells.

Created immunocompromised mouse model to study the effect of in vivo immune component on T7 phage virus. In vivo selection of tissue specific receptor binding peptide using in vivo biopanning method. Tissue targeted gene delivery to correct the blood related genetic diseases. Gene cloning, gene sequencing, synthesis of RNA probes. Protein and enzyme biochemistry Protein assay, peptide structure and amino acid sequencing, Enzyme assay, Ultra centrifugation, Ion exchange chromatography, column chromatography, HPLC, Protein and gene regulation during the development. Enzyme kinetics, Enzyme inhibition, SDS gel electrophoresis, Protein characterization.

Selection of cell receptor binding peptide and Phage display technology

- Selection of tissue receptor binding peptides using T7 phage display system. - In vivo and in vitro biopanning for selection of receptor binding peptides sequences. - Characterization of targeted cells and tissues using histochemistry and gene expression analyses. - In vivo delivery of drugs and genes to targeted tissues using microinjection.

Cancer Research

- Studying the role of pharmaceutical agent curcumin as an anti-lung cancer drug and develop it as a non-toxic cancer drug. - Role of apoptotic genes on the lung cancer cell lines. - Development of tissue targeted delivery protocol of pharmaceuticals agents for cancer and genetic diseases

Fluorescence techniques for nucleic acid sequence detection: Clinical and diagnostic applications

- Fluorescent labeling of DNA and RNA probes. - Fluorescence resonance energy transfer (FRET) protocols for DNA and RNA sequence. detection in real time (Sequence Detection System 7700, ABI, Perkin Elmer) - FRET protocols for monitoring ribozyme reactions and kinetics in real time (TaqMan, SDS 7700, ABI, Perkin Elmer). - Accessibility studies for DNA and RNA target sequences using FRET. - Fluorescence polarization protocols for monitoring ribozyme reactions (POLARstar, BMG, GmbH) and for DNA and RNA sequence detection. - Sequence detection with Syber green dye in real time quantitative PCR by Light Cycler (Roche Diagnostics, USA). - Single nucleotide polymorphism detection in real time with LightCycler hybridization probes (Roche Diagnostics, USA).

Gene detection technology: Research and Clinical applications

- Preparation of radio labeled & fluorescent labeled RNAs (ribozymes and target substrates). - In vitro transcription of RNA. - Expression of ribozymes in yeast. - Isolation and purification of cellular RNA. - RNase Protection Assay. - Kinetic characterization of ribozymes & binding kinetics using fluorescence methods. - Designing, synthesis and characterization of allosteric ribozymes induced by small drug ligands (such as theophylline & caffeine).

In utero transplantation: Clinical Research to cure the fetal genetic diseases

- Developed in utero microinjection techniques to transplant the bone marrow and stem cells to cure blood related genetic disease. - Harvest the fetal liver, bone marrow and mouse embryonic stem cells for transplantation. - Culture mouse embryonic stem cell and in vitro differentiation into the blood cells. - Fractionation of cells using flow cytometry techniques.

Standard Molecular biology techniques - Standard and site directed mutagenesis polymerase chain reaction (PCR). - Preparation and purification of plasmids. - Transformations and Transfection of DNA. - Cloning of DNA. - Solid phase synthesis of DNA (Gene Assembler, Pharmacia). - DNA sequencing & fragment analyses (ABI 310 Gene Sequencer, Perkin Elmer). - Quantitation of DNA, RNA and proteins. - Mammalian cell culture and yeast culture. - Gel electrophoresis (polyacrylamide and agarose). - Capillary gel electrophoresis (ABI 310 Gene Sequencer, Perkin Elmer). - Column/ gel/ thin layer chromatography. - Autoradiography by phosphorimager (Storm, Molecular Dynamics, USA). - High Performance Liquid Chromatography (HPLC). - Preparation and purification of chemical reagents & solvents. - Enzyme/ Protein/ purification and characterization. - Isolation of Genomic DNA, Genomic library Construction. - Radioimmunoassay.

General molecular and biochemical techniques

mRNA preparation and purification, Primer designing, Real-time PCR, RT-PCR, DNA cloning, DNA sequencing, Isolation of Genomic DNA, Genomic library Construction, Transformation, Transfection, Cell culture, Plasmid purification, RNA probe making, Different kinds of microscopy, In situ hybridization, Southern blotting, Northern blotting, Western blotting, Spectrophotometery, In utero-microinjection, Column chromatography, HPLC, PAGE, Agarose gel-electrophoresis, Enzyme assay, Protein assay, Enzyme/ Protein/ DNA purification, Histology, Phage display for tissue targeting, Radio-immunoassay,

INVITED SPEAKER AND PRESENTATIONS OF DR. SRIVASTAVAS SCIENTIFIC FINDINGS IN NATIONAL AND INTERNATIONAL CONFERENCES:

1. Srivastava A.S. Invited Speaker, STEM 2013, 9 Th Annual Conference on Biotechnology - Focusing On Latest Trend in Stem Cells, Regenerative Medicine and Tissue Engineering Mumbai, India, January 2013.

2. Srivastava A.S. "International Conference on Regenerative and Functional Medicine" (Regenerative Medicine-2012), San Antonio, USA. November 2012.

3. Sriavstava A.S. 2nd International Congress on Neurology & Epidemiology; "Impact of drugs on the natural history of neurological diseases". Nice, France. November 2012.

4. Srivastava A.S. Invited Speaker, International Expo and Conference on Analytrix & HPLC, Chicago, USA. October 2012.

5. Srivastava A.S. Invited Speaker at "International Conference on Emerging Cell Therapies" (Cell Therapy-2012) Chicago, USA. October 2012.

6. Srivastava A.S. Invited Speaker, 6th Neurodegenerative Conditions Research and Development Conference San Francisco, CA, USA. September 2012.

7. Srivastava A.S. 8th International Congress on Mental Dysfunction & Other Non-Motor Features In Parkinson's Disease and Related Disorders, Berlin, Germany. May 2012.

8. Srivastava A.S. International Conference and Exhibition on Neurology & Therapeutics Las Vegas, USA. May 2012.

9. Srivastava A.S. Montreal International Biotechnology Forum, Montreal, Quebec, Canada. May 2012.

10. Srivastava A.S. Invited Speaker, International Association of Neurorestoratology (IANR) V and 9th Global College Neuroprotection and Neuroregeneration (GCNN) conference with the 4th International Spinal Cord Injury Treatment & Trial Symposium (ISCITT) Xian City, China. May 2012.

11. Srivastava A.S. International Forum on the Mediterranean Diet, Ravello - Amalfi Coast, Italy. March 2012

12. Srivastava A.S. Hong Kong international Stem Cell Forum 2012, Hong Kong. February 2012.

13. Srivastava A.S. 4th International Conference on Drug Discovery and Therapy" (4th ICDDT 2012) Dubai, UAE, February 2012.

14. Srivastava A.S. Evolving Strategies in Hematopoietic Stem Cell Transplantation- San Diego, USA. February 2012.

15. Srivastava A.S. Hebei International Biotechnology Forum; Shijiazhuang, Hebei, China. November 2011

16. Srivastava A.S. 3rd International Conference on Drug Discovery and Therapy. Regenerative Medicine. Dubai, UAE. February 2011.

17. Srivastava A.S. 3rd Annual Congress of Regenerative Medicine & Stem Cell-2010, Shanghai, China. December 2010.

18. Srivastava A.S. 1st Annual Tetra-Congress of MolMed-Personal Medicine Congress 2010, Shanghai, China. November 2010.

19. Srivastava A.S. International Association of Neurorestoratology(IANR), American Journal of Neuroprotection and Neuroregeneration, Beijing, China. October 2010.

20. Srivastava A.S. EPS Global International Neuroscience Forum. Nha Trang, Vietnam. October 2010.

21. Srivastava A.S. EPS Global International Neuroscience Forum, Guangzhou, China. September 2010.

22. Srivastava A.S. 4th Academic Congress of International Chinese Neurosurgical Sciences. Chengdu, China. June 2010.

23. Srivastava A.S. 1st Annual World Congress of Immunodiseases and Therapy (WCIT 2010). Beijing, China. May 2010.

24. Srivastava A.S. 3rd PepCon-2010 - Protein Misfolding and Neurodegeneration. Beijing, China. March 2010

25. Srivastava A.S. Potential use of ES cells in hematopoietic and neural diseases. City of Hope National Medical Center, Duarte, California, USA. January, 2009.

26. Srivastava A.S. Differentiation of Human Embryonic Stem cell into erythrocyte and neural precursor cells: Its potential application. Cleveland Clinic, Cleveland, Ohio, USA, December, 2008.

27. Srivastava A.S. Potential of ES cell in repair of Hematopoietic and neural diseases. International Conference in Stem cell, Kerala, India, August, 2008.

28. Srivastava A. S., Singh U. and Carrier E. Embryonic stem cell improve colitis and decrease IL- 12 levels in the colitis mice. BMRP Fourth Annual Investigator Meeting, Los Angeles, USA. 2006

29. Carrier E., Shermila Kausal and Srivastava A. S. Gene Regulation During the Erythrocytic Differentiation of Embryonic Stem Cells. Blood (ASH Meeting), 2005.

30. Carrier E., Shermila Kausal and Srivastava A. S. Differentiation of Human ES cell into the Hemangioblast. Blood (AHS Meeting), 2005.

31. Srivastava A.S., Zhongling F., Victor A., Kim H.S. and Carrier E. Repair of Crohns disease with embryonic stem cells. Broad Medical Research Program, Third Annual Investigator Meeting, Los Angeles, CA, USA, 2005.

32. Srivastava A.S., Shenouda S. and Carrier E. Damaged murine brain induces ES cells into migration and proliferation. Blood:104, 779a, 2004.

33. Srivastava A.S., Shenouda S. and Carrier E. Increased expression of OCT4,SOX2 and FGF4 genes following injection of embryonic stem cell into damaged murine brain. American Society of Gene Therapy, 2004.

34. Srivastava A.S. and Carrier E.; Distribution and stability of T7 phage in mouse blood and tissues. Molecular Therapy:7, 230, 2003.

35. Moustafa M., Srivastava A.S., Nedelcu E., Minev B., Carrier E.; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. 32nd annual meeting of the international society for Experimental Hematology, 31, 274, 2003 (Paris, France).

36. Steve S., Srivastava A.S. Carrier E.; In vivo survival of hematopoietic stem cell in mouse brain.11th international symposium on recent advances in Stem cell transplantation, 89-90, 2003 (San Diego, USA).

37. Srivastava A.S., Carrier E.; Distribution and stability of T7 phage in mouse. 11th international symposium on recent advances in Stem cell transplantation, 93, 2003 (San Diego, USA).

38. Elena N., Srivastava A.S., Varki N.M., Assatourian G. and E. Carrier; Embryonic stem cells survive and proliferate after intraperitoneal In utero transplantation and produce teratocarcinomas. Blood:160b, 2002.

39. Srivastava A.S and E. Carrier; In utero targeting the fetal liver by using T7 phage display system. Blood:489b, 2002.

40. Srivastava A.S. and E. Carrier; Factor responsible for in vivo neutralization of T7 phage display vector in the blood of mice. Blood:489b, 2002.

41. Srivastava A.S. and E. Carrier; Distribution and stability of T7 phage in the mouse after intravenous administration. ICCC, Kyoto, Japan. (October 2002).

42. Srivastava A.S., T. Kaido and E. Carrier; Immunological factors that affect the in vivo fate of T7 phage in the mouse. Molecular Therapy:5, 713, 2002.

43. Srivastava A.S., E. Nedelcu and E. Carrier; Engraftment of murine embryonic stem cells after in utero transplantation. Molecular Therapy:5, 1132, 2003.

44. M. Rizzi, T. Kaido, M.Gerloni, K.Schuler, A. S. Srivastava, E.Carrier and M. Zanetti; Neonatal T cell immunity by in utero immunization. AAI 2002 annual meeting, April 20 - 24, New Orleans, Experimental Biology 2002 sponsored by 7 FASEB societies.

45. Srivastava A.S., T. Kaido and E. Carrier; Kinetics of T7 phage neutralization in the blood of normal and immunodeficient mice. Blood:407, 2001.

46. Hassan S., Jody D., Srivastava A.S., T.H. Lee, M.P. Busch, Carrier E.; Immunity without microchimerism after in utero transplantation of Hematopoietic stem cell. Blood:320, 2001.

47. Srivastava A.S., Felix Tinkov, T. Friedmann and E. Carrier; Detection of T7 phage in the fetus after Systemic administration to pregnant mice. Molecular Therapy:4, 760, 2001.

48. Pillai G.R., Srivastava A.S., Hassan S., Carrier E. Differential sensitivity of human lung cancer cell lines to curcumin. 9th Annual International Symposium on Recent Advances in Hematopoietic Stem cell Transplantation. USA. 2001.

49. Hassan S., Jody D., Srivastava A.S., Carrier E.; The role of I-E molecule on survival rate and tolerance after in utero transplantation. The 42 ASH meeting, San Francisco, USA. 2000.

50. Suzuki T., Srivastava A.S., Kurokawa T.; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, April 2 - 4, 2000, Tokyo, JAPAN.

51. Srivastava A.S., Suzuki T., Kurokawa T., Kamimoto M., Nakatsuji T.; GFP expression in pancreas of developing fish embryo under control of Carboxypeptidase A promoter. Plant and Animal Genome-VIII (PAG-VIII), Conference, San Diego, California, USA. January 9th to 12th, 2000.

52. Srivastava A.S., Suzuki T., Kurokawa T.; Molecular cloning of serine protease cDNAs from pancreas of Japanese flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, Tokyo, JAPAN. 1999.

53. Suzuki T., Srivastava A.S., Kurokawa T.; Cloning of FGFRs from Flounder embryos, and their expression during axial skeletal development. 32nd Annual Meeting of the Japanese Society of Developmental Biologists. JAPAN. 1999.

54. Suzuki T., Srivastava A.S., Kurokawa T.; Expression of Signal molecules during axial skeleton development in Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.

55. Suzuki N., Suzuki T., Srivastava A.S., Kurokawa T.; cDNA cloning and expression analysis of receptor for calcitonin and calcitonin related peptide from Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.

56. Srivastava A.S., Trigun S.K., Singh S.N.; Purification and kinetics of cytosolic aspartate aminotransferase from liver of air-breathing and non air-breathing fish. National Symposium on Comparative Physiology & Endocrinology, Raipur, INDIA. 1997.

See the article here:
Stem Cell Treatment & Cure in India | GIOSTAR

Australia - New Zealand - Asia & Pacific Rim - China - Italy

The Foundation is a privately funded philanthropic (non profit) organization advising un-well people about how to gain access to Adult Stem Cell Therapy (ASCT). The Foundation is also promoting a plan to its members on how to prevent or limit the progression of degenerative diseases and other conditions. Degenerative disease is an escalating world problem that, if not controlled, could bankrupt our health systems.

A major objective of the Foundation is to highlight that people suffering from degenerative conditions now have the option of considering Adult Stem Cell Therapy. This therapy may improve quality of life for sufferers of Arthritis, MS, Parkinsons, Diabetes, Stroke, Alzheimers, Spinal Cord injuries, Cancer or Chronic Pain to name a few. A stem cell transplant, instead of a joint replacement, is fast becoming the preferred first option for orthopedic surgeons.

The Foundation intends to educate parents/carers of children suffering from a debilitating or degenerative condition like Cerebral Palsy, Muscular Dystrophy, Autism, Spinal injuries, Cystic fibrosis, ADHD etc. Stem cell treatments have progressed in leaps and bounds for these conditions. There are now state of the art clinics that specialize in treating the afore-mentioned conditions. Children can usually benefit substantially from an early intervention by stem cell therapies and other protocols because they are still growing. As an example: spending time in a mild hyperbaric chamber (HBO) can also be beneficial. Just fill out the Application Form for an experimental transplant and we will be only too happy to advise.

The ASCF has become a global Information Centre for stem cell therapy. The centre will only support clinics that have demonstrated they abide by the highest medical standards and have a proven track record of administering these types of therapies, in Australia and overseas. We can now advise locally which gives peace of mind to our members who are contemplating a procedure of this nature.

Creating awareness of the availability of stem cell therapy and that it has become viable for consideration.

To raise money from benefactors, including private and commercial sponsorships.

To provide medical and research reports on degenerative disease to doctors and health professionals.

To run awareness programs on Lifestyle Medicine promoting healthy foods that may prevent the onset of degenerative diseases. This includes stem cell stimulating natural products that are backed by science.

To provide information to schools on healthy diet and lifestyle plans. To provide scholarships and fellowships for the study of degenerative diseases and their treatment.

To support Adult Stem Cell research by leading Universities and Not For Profit organizations.

To open representative offices in other countries. Such offices are already established in Thailand, NZ, South Africa, India, UK and France

It is a free service giving doctors in full security and full control the ability to record and share patient stem cell data with other doctors. The following is an overview of the Registrys main features:

Australasian Stem Cell Registry Overview - Read more >>>

The ASCF has also introduced a new funding model for stem cell transplants - this new financing model is funded by the patients and their supporters.

The Foundation receives no government funding so we exist on the generosity of our members, the public and corporations. We hope if we can help improve your health outcomes that you may see your way clear at some future time to consider assisting with either your time or money to this worthwhile cause.

We would also like to point out that there are medical conditions today that are still beyond the scope of this new and exciting branch of medical science, which unfortunately means not everybody can be treated with stem cells at this stage. If you are in this category, it is even more important you follow the ASCF Prevention Plan (see below) and keep your health in the best possible state while science catches up. Science is moving very fast in the area of Regenerative Medicine.

See the rest here:
Stem cell - ADULT STEM CELL THERAPY IS AVAILABLE NOW!

Home Stem Cell Therapy | Cellular Prolotherapy

Ross Hauser, MD

Ross Hauser, MD: the use of Stem Cell Therapy in the treatment of joint and spine degeneration.

Stem cell therapy is exploding in the medical field, and for good reason. Stem cells have the potential to regenerate into any type of body tissue. The amazing thing about stem cells is that when you inject them into the body, they know what kinds of cells your body needs for example, meniscus cells or cartilage cells. It is a very exciting time for medicine, especially in the field of regenerative medicine. In our office we often refer to this as Cellular Prolotherapy.

In Stem Cell Therapy we use a persons own healing cells from bone marrow, fat, and blood (alone or in various combinations) and inject them straight to the area which has a cellular deficiency.

The goal is the same: to stimulate the repair of injured tissues. Stem cells aid in fibroblastic proliferation where cell growth, proteosynthesis, reparation, the remodeling of tissues, and chondrocyte proliferation occurs. Our bone marrow contains stem cells,also termed mesenchymal stem cells and progenitor cells, among other names. These immature cells have the ability to become tissues like cartilage, bone, and ligaments.

Consequently, researchers and clinicians are focusing on alternative methods for cartilage preservation and repair. Recently,cell-basedtherapyhas become a key focus of tissue engineering research to achieve functional replacement of articular cartilage.1

Not all injuries require stem cells to heal. For many patients the success rate with traditionalProlotherapyin this office is in the 90%+ range for all patients. However, for those cases of advanced arthritis, meniscus tears, labral tears, bone-on-bone, or aggressive injuries, our Prolotherapy practitioners may choose to use stem cell injections to enhance the healing, in combination with dextrose Prolotherapy to strengthen and stabilize the surrounding support structures formeniscus repair.

In our research published inThe Open Stem Cell Journal,Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy(Prolotherapy). We not only showed the benefit of bone marrow derived stem cells as a Prolotherapy proliferant solution, but also that this exciting field of medicine needs doctors and scientisists working together to expand research and technique guidelines.

Typically the tissue that we are trying to stimulate to repair with Stem Cell Therapy or Cellular Prolotherapy is articular cartilage, but we can also proliferate soft tissues structures such as ligament and tendons. This is new technology so we are studying it as we use it to treat patients.

We chose to review this study to support our research and to inform people about the human studies usingbone marrow stem cellsfor articular cartilage lesions. Articular cartilage is a type of cartilage that covers joint surfaces and is most susceptible to injury compared to other types of cartilage.

Researchers at Cairo University School of Medicine and the University of Pittsburgh School of Medicine reported on the use of bone marrow mesenchymal stem cells and aplatelet-richfibrin scaffold to heal full-thickness cartilage defects in five patients. The researchers studied the treatment results from the bone marrow mesenchymal stem cells which were used in a platelet rich fibrin glue, placed on the tear and covered with a flap of the patients cartilage.

Platelets were used as a scaffold because platelets contain various growth factors that stimulate cartilage regeneration. The researchers expected that the biological effect of multiplegrowth factorson tissue regeneration is greater that of a single growth factor.

Results

The patients showed significant functional improvement. Two of the patients underwent arthroscopy after the transplantation and showed near normal articular cartilage. Three postoperative MRIs revealed complete healing and congruent cartilage tissue, whereas two patient MRIs showed incomplete congruity in the cartilage tissue.

Conclusion

Osteoarthritis is a cartilage degenerative processNo treatment is still available to improve or reverse the process. Stem cell therapy opened new horizons for treatment of many incurable diseasesIn this research four patients with knee osteoarthritis were selected for the study. They were aged 55, 57, 65 and 54 years, and had moderate to severe knee Osteoarthritis. After their signed written consent, 30 mL of bone marrow were taken and cultured for MSC growth. After having enough MSCs in culture (4-5 weeks) and taking in consideration all safety measures, cells were injected in one knee of each patient.

The walking time for the pain to appear improved for three patients and remained unchanged for one. On physical examination, the improvement was mainly for crepitus. It was minor for the improvement of the range of motion.

Results were encouraging, but not excellent. Improvement of the technique may improve the results.4

Platelet Rich Plasma contains a myriad of substances that stimulate healing:

Numerous studies have shown that PRP enhances the effects of Stem Cell Therapy5,6As the study above notes Results were encouraging, but not excellent. Improvement of the technique may improve the results. Platelet Rich Plasma therapy improves the technique and improves the results.

Our ultimate goal withallforms of Prolotherapy is to get the patients back to doing the things that they want to do without pain. It is our hope that the Stem Cell Therapy (Cellular Prolotherapy) treatments will form functionally, structurally, and mechanically equal to, if not better than, living tissue which has been designed to replace (or work alongside of) damaged tissue. It is hard to prove the above statement because we cannot sacrifice human beingsafterProlotherapy to see if the tissue looks and acts normally. Wecan, however, report that the majority of our patients who receive Stem Cell Therapy along with traditional Hackett-Hemwall Prolotherapy get back to activities and have dramatically decreased pain levels using this comprehensive approach.

Links to our other articles for your specific conditions

A page with more information on stem cell injection treatments combined with Prolotherapy and PRP Treatments for back pain.

In this article wediscusses research that showsthatstem cell injection therapywill aid in the repair ofarticular cartilageandmeniscus tears. The treatment relieves symptoms of stiffness,pain, disability, and inability to walk as commonly reported by our patients diagnosed with knee osteoarthritis.

Many patients have many questions about stem cell tretament for knee osteoarthritis, lets hear yours.

References for this article

1.Mazor M, Lespessailles E, Coursier R, et al.Mesenchymal stem-cell potential in cartilage repair: an update. J Cell Mol Med. 2014 Oct 29. doi: 10.1111/jcmm.12378. 2. Diekman BO, Guilak F.Stem cell-based therapies for osteoarthritis: challenges and opportunities. Curr Opin Rheumatol. 2013 Jan;25(1):119-26. doi: 10.1097/BOR.0b013e32835aa28d. 3. Hauser RA, Orlofsky A.Regenerative injection therapy with whole bone marrow aspirate for degenerative joint disease: a case series.Clin Med Insights Arthritis Musculoskelet Disord. 2013 Sep 4;6:65-72. doi: 10.4137/CMAMD.S10951. eCollection 2013. 4. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011 May;14(2):211-5. doi: 10.1111/j.1756-185X.2011.01599.x. Epub 2011 5. Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V, Jacobs CR. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. 2009 Sep;15(3):431-5. 6. Kasten P, Vogel J, Beyen I, Weiss S, Niemeyer P, Leo A, Lginbuhl R. Effect of platelet-rich plasma on the in vitro proliferation and osteogenic differentiation of human mesenchymal stem cells on distinct calcium phosphate scaffolds: the specific surface area makes a difference. J Biomater Appl. 2008 Sep;23(2):169-88. Epub 2008 Jul 16.

Read the original here:
Stem Cell Therapy | Cellular Prolotherapy | Caring Medical